

# Sally Arai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8135385/publications.pdf>

Version: 2024-02-01

112  
papers

6,801  
citations

159358

30  
h-index

64668

79  
g-index

112  
all docs

112  
docs citations

112  
times ranked

7249  
citing authors

#	ARTICLE	IF	CITATIONS
1	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 389-401.e1.	2.0	2,636
2	Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 266-274.	2.0	331
3	Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. <i>Blood</i> , 2011, 117, 4651-4657.	0.6	319
4	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1419-1431.	15.2	273
5	Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. <i>Blood</i> , 2016, 127, 1656-1665.	0.6	255
6	Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. <i>Blood</i> , 2017, 130, 900-902.	0.6	207
7	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (SMT CTN 1203). <i>Lancet Haematology</i> , 2018, 6, e132-e143.	2.2	200
8	Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. <i>Blood</i> , 2011, 118, 4242-4249.	0.6	196
9	TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. <i>Blood</i> , 2009, 114, 1099-1109.	0.6	150
10	Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. <i>Blood</i> , 2021, 138, 2278-2289.	0.6	124
11	Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 449-455.	2.0	113
12	Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. <i>Blood</i> , 2012, 119, 6145-6154.	0.6	107
13	Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. <i>Heart Rhythm</i> , 2014, 11, 158-162.	0.3	102
14	Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. <i>Blood</i> , 2012, 120, 2545-2552.	0.6	101
15	Final results from a defibrotide treatment IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. <i>British Journal of Haematology</i> , 2018, 181, 816-827.	1.2	95
16	Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 143-155.	2.5	92
17	Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma. <i>Science Translational Medicine</i> , 2013, 5, 214ra171.	5.8	84
18	Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. <i>Haematologica</i> , 2012, 97, 451-458.	1.7	77

#	ARTICLE	IF	CITATIONS
19	Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 337-344.	2.0	76
20	A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. <i>Clinical Cancer Research</i> , 2016, 22, 319-327.	3.2	68
21	Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1&sup2; dose de-escalation study. <i>Lancet Haematology</i> , 2015, 2, e367-e375.	2.2	64
22	The Cost of Hematopoietic Stem-Cell Transplantation in the United States. <i>American Health and Drug Benefits</i> , 2017, 10, 366-374.	0.5	62
23	An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2017, 130, 360-367.	0.6	52
24	CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR&sup2;refractory large B-cell lymphoma. <i>Blood</i> , 2021, 137, 2321-2325.	0.6	51
25	Assessment of Joint and Fascia Manifestations in Chronic Graft&sup2;Versus&sup2;Host Disease. <i>Arthritis and Rheumatology</i> , 2014, 66, 1044-1052.	2.9	50
26	Donor-derived MDS/AML in families with germline GATA2 mutation. <i>Blood</i> , 2018, 132, 1994-1998.	0.6	48
27	Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation. <i>JACC: Heart Failure</i> , 2020, 8, 461-468.	1.9	46
28	Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. <i>JCI Insight</i> , 2019, 4, .	2.3	46
29	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	3.3	45
30	Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. <i>Blood</i> , 2016, 128, 2350-2358.	0.6	43
31	Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. <i>Blood Advances</i> , 2021, 5, 4278-4284.	2.5	36
32	Organ responses with daratumumab therapy in previously treated AL amyloidosis. <i>Blood Advances</i> , 2020, 4, 458-466.	2.5	35
33	A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis. <i>JACC: Heart Failure</i> , 2019, 7, 958-966.	1.9	31
34	Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2014, 99, 1618-1623.	1.7	29
35	Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2015, 100, 690-695.	1.7	29
36	Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. <i>Blood Advances</i> , 2021, 5, 4465-4475.	2.5	28

#	ARTICLE	IF	CITATIONS
37	Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2018, 2, 681-690.	2.5	27
38	Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. <i>Blood Advances</i> , 2018, 2, 1882-1888.	2.5	27
39	Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review. <i>Blood Advances</i> , 2020, 4, 815-818.	2.5	27
40	Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4474-4482.	2.5	25
41	Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 393-399.	2.0	24
42	Natural killer cells: can they be useful as adoptive immunotherapy for cancer?. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 163-172.	1.4	23
43	Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and S $\alpha$ zary Syndrome. <i>JAMA Dermatology</i> , 2018, 154, 728.	2.0	23
44	Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021, 5, 3147-3151.	2.5	21
45	Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1145-1154.	2.0	19
46	Total Lymphoid Irradiation $\alpha$ Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 837-843.	2.0	18
47	A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 932.e1-932.e11.	0.6	18
48	Anti $\alpha$ Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 373-380.	2.0	15
49	Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and S $\alpha$ zary Syndrome (SS). <i>Blood</i> , 2014, 124, 2544-2544.	0.6	15
50	Post $\alpha$ hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics. <i>Blood Advances</i> , 2022, 6, 2707-2721.	2.5	14
51	Validation of the Hematopoietic Cell Transplantation $\alpha$ Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1744-1748.	2.0	12
52	Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. <i>Blood Advances</i> , 2019, 3, 2454-2464.	2.5	12
53	Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control.. <i>Blood</i> , 2009, 114, 654-654.	0.6	12
54	Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213). <i>Blood</i> , 2020, 136, 45-46.	0.6	11

#	ARTICLE	IF	CITATIONS
55	Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center Report. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 215.e1-215.e10.	0.6	11
56	Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e328-e332.	2.0	10
57	Grading cardiac response in <scp>AL</scp> amyloidosis: implications for relapse and survival. <i>British Journal of Haematology</i> , 2019, 186, 144-146.	1.2	9
58	Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2664-2671.	1.3	9
59	HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. <i>Blood Advances</i> , 2017, 1, 1347-1357.	2.5	8
60	Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1727-1732.	2.0	8
61	Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2021, 56, 368-375.	1.3	8
62	Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. <i>Blood Advances</i> , 2021, 5, 4549-4559.	2.5	8
63	Results Of The Large Prospective Study On The Use Of Defibrotide (DF) In The Treatment Of Hepatic Veno-Occlusive Disease (VOD) In Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome - Updated Results Of a Treatment IND (T-IND) Expanded Access Protocol. <i>Blood</i> , 2013, 122, 700-700.	0.6	8
64	Hematologic Responses and Cardiac Organ Improvement in Patients with Heavily Pretreated Cardiac Immunoglobulin Light Chain (AL) Amyloidosis Receiving Daratumumab. <i>Blood</i> , 2016, 128, 4525-4525.	0.6	8
65	Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant. <i>Blood</i> , 2012, 120, 3701-3701.	0.6	7
66	Rituximab in hematopoietic cell transplantation. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 971-982.	1.4	5
67	Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 590.e1-590.e8.	0.6	5
68	Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 405.e1-405.e6.	0.6	4
69	A Case Report of Refractory Immune Thrombocytopenia (ITP) Following Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) Successfully Treated with Off-Label Use of Daratumumab. <i>Blood</i> , 2018, 132, 4976-4976.	0.6	4
70	Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants. <i>Blood</i> , 2020, 136, 47-48.	0.6	4
71	Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents. <i>Blood</i> , 2019, 134, 2022-2022.	0.6	4
72	CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 741-741.	0.6	4

#	ARTICLE	IF	CITATIONS
73	Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity. <i>Blood</i> , 2020, 136, 32-33.	0.6	4
74	CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020, 136, 28-29.	0.6	3
75	Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 8026-8026.	0.8	3
76	Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Host Conditioning with Total Lymphoid Irradiation and Anti-Thymocyte Globulin Confirm a Low Incidence of Graft Versus Host Disease (GVHD) and Retained Graft Anti-Tumor Activity. <i>Blood</i> , 2006, 108, 603-603.	0.6	3
77	Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant. <i>Blood</i> , 2021, 138, 878-878.	0.6	3
78	Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era. <i>Transplantation and Cellular Therapy</i> , 2022, , .	0.6	3
79	Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study. <i>Blood</i> , 2020, 136, 22-23.	0.6	2
80	Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results in Low Chronic Gvhd. <i>Blood</i> , 2008, 112, 466-466.	0.6	2
81	Mgta-145 + Plerixafor Provides G-CSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study. <i>Blood</i> , 2021, 138, 3885-3885.	0.6	2
82	Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study. <i>Blood</i> , 2021, 138, 98-98.	0.6	2
83	Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile. <i>Bone Marrow Transplantation</i> , 2015, 50, 1004-1006.	1.3	1
84	Cytokine Induced Killer (CIK) Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2006, 108, 412-412.	0.6	1
85	Rituximab Infusion Two Months after HCT Decreases Alloreactive B Cell Responses While Recipient Plasma Cells Persist. <i>Blood</i> , 2008, 112, 2234-2234.	0.6	1
86	Trends In Incidence, Presentation, and Outcomes Of Chronic Graft-Versus-Host Disease In Allogeneic Transplantation- Report From The Center For International Blood and Marrow Transplant Research. <i>Blood</i> , 2013, 122, 3309-3309.	0.6	1
87	Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms. <i>Blood</i> , 2015, 126, 3232-3232.	0.6	1
88	Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial. <i>Blood</i> , 2015, 126, 737-737.	0.6	1
89	Long-Term Outcomes of Myeloablative Conditioning and Matched-Related Donor Hematopoietic Cell Transplantation for Patients with High-Risk and Advanced-Stage Hematolymphoid Malignancies. <i>Blood</i> , 2008, 112, 4383-4383.	0.6	0
90	Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation. <i>Blood</i> , 2008, 112, 4348-4348.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hematopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma.. Blood, 2008, 112, 2194-2194.	0.6	0
92	AL Amyloidosis: Prognosis of Cardiac Involvement Reconsidered.. Blood, 2009, 114, 4872-4872.	0.6	0
93	Correlation of the NIH and Vienna Skin Scores with Provider and Patient-Reported Skin Changes in Chronic Graft-Versus-Host Disease (GVHD).. Blood, 2009, 114, 2256-2256.	0.6	0
94	A Dose Escalation Trial of Imatinib for Steroid Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFR $\alpha$ Antibody Analysis.. Blood, 2009, 114, 3304-3304.	0.6	0
95	AL Amyloidosis and Concomitant Myeloma: Time to Reconsider Assumptions. Blood, 2010, 116, 4044-4044.	0.6	0
96	Chronic Graft-Versus-Host Disease Responds to Imatinib and Pre Transplant/Donor Anti-PDGFR $\alpha$ Antibodies Predict for Chronic Graft-Versus-Host Disease Development. Blood, 2010, 116, 2320-2320.	0.6	0
97	A Pilot Study of Melphalan, Lenalidomide and Dexamethasone In AL Amyloidosis: Interim Results. Blood, 2010, 116, 1946-1946.	0.6	0
98	Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels. Blood, 2011, 118, 3009-3009.	0.6	0
99	A Phase 1 Open Label, Dose Escalation Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft-Versus-Host Disease. Blood, 2011, 118, 1986-1986.	0.6	0
100	Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic Transplantation for Patients with Myelodysplastic Syndrome, Therapy-Related Myeloid Neoplasms, and Myeloproliferative Neoplasms.. Blood, 2012, 120, 3087-3087.	0.6	0
101	Recommended Tools for Joint Chronic Graft-Versus-Host Disease: Results From the Chronic Gvhd Consortium. Blood, 2012, 120, 464-464.	0.6	0
102	Influence Of Organ Scores On Mortality In Chronic GVHD: Results From The Chronic GVHD Consortium. Blood, 2013, 122, 4614-4614.	0.6	0
103	Use of High-Throughput Sequencing (HTS) of TCR $\beta$ to Determine the Kinetics of Graft-Versus-Lymphoma (GVL) Effect and T-Cell Repertoire Profiles after Allogeneic Transplant. Blood, 2014, 124, 2473-2473.	0.6	0
104	Updated Results from a Large, Ongoing, Treatment IND Study Using Defibrotide for Patients with Hepatic Veno-Occlusive Disease. Blood, 2014, 124, 2470-2470.	0.6	0
105	Costs of Hematopoietic Stem Cell Transplantation and Associated Conditioning Regimens. Blood, 2015, 126, 3270-3270.	0.6	0
106	Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation.. Journal of Clinical Oncology, 2016, 34, 7046-7046.	0.8	0
107	Graded Cardiac Response Correlates with Relapse and Survival in AL Amyloidosis. Blood, 2018, 132, 4486-4486.	0.6	0
108	<i>Selective Targeting of Immune Modulatory Proteins to Mitigate Fibrosis and Inflammation in Sclerodermatous Graft-Vs-Host Disease</i>. Blood, 2021, 138, 644-644.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Long-Term Outcomes of Patients with Peripheral T-Cell Lymphoma after Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 2020, 136, 33-34.	0.6	0
110	Survival Following Post-HCT Relapse in Adult Acute Lymphoblastic Leukemia Has Improved in the Era of Novel Immunotherapies: A Single Institution Analysis. <i>Blood</i> , 2020, 136, 48-49.	0.6	0
111	Outcomes after Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma. <i>Blood</i> , 2020, 136, 11-12.	0.6	0
112	Outcomes after Second Allogeneic Transplantation and Donor Lymphocyte Infusion for Relapse after a First Allogeneic Transplant. <i>Blood</i> , 2020, 136, 22-23.	0.6	0